Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma

NCT01698801 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01698801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01698801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2012
Completion date
June 26, 2018
Enrollment
26 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma